Navigation Links
NCCN Posts Comparative Effectiveness White Paper for Public Comment
Date:11/9/2009

The National Comprehensive Cancer Network (NCCN) has posted a draft white paper for public comment that details a draft paradigm for near-term comparative effectiveness clinical evaluations based upon existing data. The document introduces the NCCN Comparative Therapeutic Index(TM) (CTI), a consensus-based process that compares the risk-versus-benefit of different treatment options recommended in the NCCN Clinical Practice Guidelines in Oncology(TM). The paper will be posted for public comment through November 23, 2009.

FORT WASHINGTON, Pa., Nov. 9 /PRNewswire-USNewswire/ -- Drawing on the expertise from the world's thought leaders in oncology, the National Comprehensive Cancer Network (NCCN) Oncology Comparative Effectiveness Work Group has developed a systematic process for applying existing data in comparative effectiveness clinical evaluations in the field of oncology that will benefit both physicians and patients. These recommendations are detailed in a draft white paper currently posted on NCCN.org that will be available for public comment through November 23, 2009.

The NCCN Clinical Practice Guidelines in Oncology(TM) are widely recognized and used as the standard of care in oncology in both the academic and community settings and significantly influence appropriate practice patterns, prescribing behavior, and coverage policy. With ready access to oncology experts in all relevant specialties, NCCN convened the NCCN Oncology Comparative Effectiveness Work Group comprised of expert members representing patients, clinicians, managed care, pharma/biotech, and health policy with the intent of driving the national policy process on comparative effectiveness and improving patient care.

The NCCN Work Group drafted a white paper, entitled "The 'NCCN Comparative Therapeutic Index(TM)' as a Paradigm for Near Term Comparative Effectiveness Analyses of Existing Data in Oncology", which introduces the NCCN Comparative Therapeutic Index(TM) (CTI). The NCCN CTI is a clinical evaluative method that communicates the ratio of the effectiveness of a proposed treatment versus its potential toxicity. Resource utilization issues are also addressed in the document.

The NCCN CTI model is based upon the evaluation of available scientific data integrated with the expert judgment of leading oncologists. The implementation of the NCCN CTI is proposed to be a gradual, progressive approach with an eventual goal of system-wide adoption into all of the NCCN Guidelines. Given the NCCN Guidelines' stature and credibility in the cancer community, the NCCN Work Group believes they serve as an ideal channel to disseminate comparative effectiveness results for adoption into practice.

The NCCN Work Group will consider the public's feedback and develop a second iteration of the white paper that will be presented at the NCCN Oncology Summit on December 7, 2009.

NCCN seeks to continue its leadership role in developing and communicating scientific, evaluative information to inform and improve decision-making to assure that patients have available the safest and most effective options for their cancer care.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center / Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit NCCN.org.

SOURCE National Comprehensive Cancer Network


'/>"/>
SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter
2. Irell & Manella Posts Strong Year for Corporate Transactions
3. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
4. FinCor Holdings Posts Strong Fourth Quarter and Year-End Results
5. Averting postsurgical infections in kids: Give antibiotics within hour before first incision
6. Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com
7. Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets
8. NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A
9. Cord Blood America Posts Letter to Shareholders: New Administrations Potential Enhanced Stem Cell Research Initiative Should Benefit the Company and Its Shareholders
10. Tarpon Fund Posts Strong Early Results : Innovative Fund From Islamorada Investment Management Gains 18.5% in November
11. NursingCrossing Posts 12,000-Plus Nursing Jobs in a Week; Stresses the Need for Better Training and Working Conditions for Nurses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: